324 related articles for article (PubMed ID: 34112147)
1. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors.
Wang S; Sun J; Chen K; Ma P; Lei Q; Xing S; Cao Z; Sun S; Yu Z; Liu Y; Li N
BMC Med; 2021 Jun; 19(1):140. PubMed ID: 34112147
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?
Kazemi MH; Sadri M; Najafi A; Rahimi A; Baghernejadan Z; Khorramdelazad H; Falak R
Front Immunol; 2022; 13():1018962. PubMed ID: 36389779
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating lymphocyte therapy: Clinical aspects and future developments in this breakthrough cancer treatment.
Lee H; Kim K; Chung J; Hossain M; Lee HJ
Bioessays; 2023 Jul; 45(7):e2200204. PubMed ID: 37166068
[TBL] [Abstract][Full Text] [Related]
4. Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges.
Zhao Y; Deng J; Rao S; Guo S; Shen J; Du F; Wu X; Chen Y; Li M; Chen M; Li X; Li W; Gu L; Sun Y; Zhang Z; Wen Q; Xiao Z; Li J
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077696
[TBL] [Abstract][Full Text] [Related]
5. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
[TBL] [Abstract][Full Text] [Related]
6. Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies.
Zhao D; Zhu D; Cai F; Jiang M; Liu X; Li T; Zheng Z
Technol Cancer Res Treat; 2023; 22():15330338231204198. PubMed ID: 38037341
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions.
Granhøj JS; Witness Præst Jensen A; Presti M; Met Ö; Svane IM; Donia M
Expert Opin Biol Ther; 2022 May; 22(5):627-641. PubMed ID: 35414331
[TBL] [Abstract][Full Text] [Related]
8. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
Schiltz PM; Beutel LD; Nayak SK; Dillman RO
J Immunother; 1997 Sep; 20(5):377-86. PubMed ID: 9336745
[TBL] [Abstract][Full Text] [Related]
9. TIL Therapy: Facts and Hopes.
Monberg TJ; Borch TH; Svane IM; Donia M
Clin Cancer Res; 2023 Sep; 29(17):3275-3283. PubMed ID: 37058256
[TBL] [Abstract][Full Text] [Related]
10. The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications.
Aydin AM; Bunch BL; Beatty M; Hajiran A; Dhillon J; Sarnaik AA; Pilon-Thomas S; Poch MA
Front Immunol; 2021; 12():628063. PubMed ID: 33717150
[TBL] [Abstract][Full Text] [Related]
11. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy.
Betof Warner A; Hamid O; Komanduri K; Amaria R; Butler MO; Haanen J; Nikiforow S; Puzanov I; Sarnaik A; Bishop MR; Schoenfeld AJ
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38423748
[TBL] [Abstract][Full Text] [Related]
12. CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling.
Fix SM; Forget MA; Sakellariou-Thompson D; Wang Y; Griffiths TM; Lee M; Haymaker CL; Dominguez AL; Basar R; Reyes C; Kumar S; Meyer LA; Hwu P; Bernatchez C; Jazaeri AA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35882447
[TBL] [Abstract][Full Text] [Related]
13. Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.
Mullinax JE; Egger ME; McCarter M; Monk BJ; Toloza EM; Brousseau S; Jagasia M; Sarnaik A
Cancer J; 2022 Jul-Aug 01; 28(4):285-293. PubMed ID: 35880938
[TBL] [Abstract][Full Text] [Related]
14. Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.
Kumar A; Watkins R; Vilgelm AE
Front Immunol; 2021; 12():690499. PubMed ID: 34140957
[TBL] [Abstract][Full Text] [Related]
15. Modeling
Knochelmann HM; Rivera-Reyes AM; Wyatt MM; Smith AS; Chamness R; Dwyer CJ; Bobian M; Rangel Rivera GO; Horton JD; Lilly M; Romeo MJ; Timmers CD; Rubinstein MP; Neskey DM; Paulos CM
Oncoimmunology; 2021; 10(1):1959101. PubMed ID: 34408920
[TBL] [Abstract][Full Text] [Related]
16. Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors?
Li B
Front Immunol; 2022; 13():973881. PubMed ID: 36341370
[TBL] [Abstract][Full Text] [Related]
17. [Application of gene therapy in tumor adoptive immunotherapy].
Wang C; Zhao Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Apr; 25(2):482-6. PubMed ID: 18610648
[TBL] [Abstract][Full Text] [Related]
18. Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future.
Betof Warner A; Corrie PG; Hamid O
Clin Cancer Res; 2023 May; 29(10):1835-1854. PubMed ID: 36485001
[TBL] [Abstract][Full Text] [Related]
19. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy.
Tran KQ; Zhou J; Durflinger KH; Langhan MM; Shelton TE; Wunderlich JR; Robbins PF; Rosenberg SA; Dudley ME
J Immunother; 2008 Oct; 31(8):742-51. PubMed ID: 18779745
[TBL] [Abstract][Full Text] [Related]
20. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.
Rohaan MW; van den Berg JH; Kvistborg P; Haanen JBAG
J Immunother Cancer; 2018 Oct; 6(1):102. PubMed ID: 30285902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
